Bioventus invested US $2.5MM in the ongoing clinical study of CartiHeal’s Agili-C™ implant for the treatment of joint surface lesions. The infusion adds to a previous raise of $18.3MM and brings CartiHeal’s funding total to ~$21MM.
The Investigational Device Exemption trial kicked off in early 4Q17 with enrollment of 16 patients; since then, that number has risen over 30.
The multinational study will enroll 250 patients minimum with an objective to demonstrate the superiority of Agili-C vs. microfracture and debridement to treat cartilage or osteochondral defects.
Bioventus invested US $2.5MM in the ongoing clinical study of CartiHeal's Agili-C™ implant for the treatment of joint surface lesions. The infusion adds to a previous raise of $18.3MM and brings CartiHeal's funding total to ~$21MM.
The Investigational Device Exemption trial kicked off in early 4Q17 with enrollment of 16 patients; since then,...
Bioventus invested US $2.5MM in the ongoing clinical study of CartiHeal’s Agili-C™ implant for the treatment of joint surface lesions. The infusion adds to a previous raise of $18.3MM and brings CartiHeal’s funding total to ~$21MM.
The Investigational Device Exemption trial kicked off in early 4Q17 with enrollment of 16 patients; since then, that number has risen over 30.
The multinational study will enroll 250 patients minimum with an objective to demonstrate the superiority of Agili-C vs. microfracture and debridement to treat cartilage or osteochondral defects.
Copy to clipboard 
